Men who were taking medication known to affect androgen production and/or testosterone were likewise excluded. Since Huggins' work, subsequent research has failed to definitively link testosterone therapy to a progression of prostate cancer in the untreated patient or recurrence in the treated patient. The other men in the study already had metastatic disease at the time of testosterone initiation. The relationship between testosterone therapy and the development of prostate cancer has been debated. Men were eligible for inclusion in the study if they had testosterone in the normal range, an unremarkable reproductive history and physical exam, and 2 semen samples with a sperm concentration of ≥20 million/mL. Using stricter criteria for inclusion (only RCTs), Cai et al.324 demonstrated minor improvements in triglycerides (-13.5 mg/dL) among testosterone treated men in 4 RCTs of men with testosterone deficiency. When only RCTs of men with baseline total testosterone values 326 It is unlikely that these changes represent clinically meaningful differences. From these research findings, it is evident that most studies have focused on the impact of a single dietary modification on testosterone deficiency, without considering multiple or overall dietary patterns. Although the dietary OBS alone did not demonstrate a statistically significant association with testosterone deficiency in males, the composite OBS showed a robust inverse correlation. Research on the relationship between diet and disease has consistently been a prominent area of interest, and this holds true for studies focusing on testosterone deficiency as well. A significant inverse correlation was observed between lifestyle OBS and testosterone deficiency, whereas no such association was found for dietary OBS. The highest OBS group exhibited a 38% reduction in the risk of testosterone deficiency compared to the lowest OBS group. Population, we primarily identified an inverse association between OBS and testosterone deficiency in males. As shown in Figure 3, no significant association was observed between OBS and testosterone deficiency across the stratified age groups. Older meta-analyses from 2007 and 2005 similarly demonstrated no impact of testosterone on lipid profiles.312, 327 No differences were identified in total cholesterol, low-density lipoproteins, or HDL. A second large RCT by Snyder et al.319 used the Functional Assessment of Chronic Illness Therapy-Fatigue scales (range 0-52) in 474 men treated with testosterone for 12 months. Duration of studies and mode of administration did not appear to impact outcomes. Two of the retrospective studies included in the FDA review pointed to an increased risk of cardiovascular events in men on testosterone therapy. Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. Men with total testosterone level 315 ng/dL declined from 100% at 4 weeks to 86%, 75%, and 14% by 12, 20, and 24 weeks, respectively.Mean peak total testosterone levels are dose-dependent, with a mean of 746, 866, and 913 ng/dL noted with 8, 10, and 12 pellets administered (not BMI adjusted).446 The duration of effect is similar, however, and is relatively independent of dosing. PSA recurrence in men on testosterone therapy should be evaluated in the same fashion as untreated men. There has been a concern that testosterone therapy might cause progression of previously existing, but undiagnosed, prostate cancer or that testosterone might cause high-grade prostatic intraepithelial neoplasias (PIN) to progress into frank carcinoma. There are limited data in men on active surveillance who are candidates for testosterone therapy. Six patients experienced biochemical recurrence, all of whom had intermediate- or high-risk prostate cancer. Administration of 750 mg of IM testosterone undecanoate at weeks 0, 4, and every 10 weeks thereafter maintained total testosterone levels between 300-1,000 ng/dL for 94% of men.438 No men experienced maximal values Adverse Effects. Furthermore, the concept of testosterone 'crash' is well recognized by clinicians, with large differences between peak and trough levels potentially leading patients to become symptomatic towards the end of the cycle despite having therapeutic trough testosterone levels. Initial studies of testosterone patches demonstrated increases in total testosterone from a baseline 167 ng/dL to a peak of 1,154 ng/dL at 5.7 hours, with a decrease to 490 ng/dL over the next 12 hours.424 Following removal, the observed testosterone half-life was 116 minutes.425, 426 A multicenter, open label study confirmed mirroring of the circadian rhythm when the patch is applied in the evening with a morning peak of 740 ng/dL and a night-time trough of 213 ng/dL.427 If insufficient testosterone levels are achieved with one topical agent, including with dose adjustments, substitution with another topical agent is a viable treatment strategy.420 Differences in age, geography, date of initial testing (testosterone immunoassay testing was more commonly used before 2005), comorbid conditions, and baseline and therapeutic testosterone levels across studies introduce heterogeneity in the pooled population. Cyanidin-3-glucoside also enhances testicular expression of the steroidogenic proteins STAR, CYP11A1 and HSD3B, as well as the LH receptor, in mice exposed to cadmium, a major neuro-endocrine disruptor . These flavonoids may improve steroidogenesis through their inhibitory activity against COX2 and their capacities to modulate the activity of the MAPK signaling pathway 151,152, promoting STAR protein expression and activity in Leydig cells. However, others have shown that green tea polyphenols rather inhibit androgen synthesis in rat Leydig cells via inhibition of the PKA/PKC signaling pathways, and of the CYP11A1 and HSD17B3 enzymes . Others have reported that soybean meal and genistin/daidzin diets decrease testosterone production regardless of the age of male rats due to decreases in STAR and HSD17B protein levels . However, Leydig cell proliferation and increased levels of STAR, CYP11A1, HSD3B and CYP17A1 are observed following exposure of perinatal male rats to soy isoflavones . Although several studies suggest that isoflavones contribute to lower testosterone levels in men, a meta-analysis of 32 studies concluded that neither soy foods nor isoflavone supplementation had significant effects on testosterone levels .
